References
- Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moye LA, Hill MD, Wojner AW. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004; 351(21)2170–2178, CLOTBUST Investigators.
- Angles-Cano E. A spectrophotometric solid-phase fibin-tissue plasminogen activator activity assay (SOFIA–tPA) for high-fibrin-affinity tissue plasminogen activators. Anal Biochem 1986; 153: 201–210
- Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965; 13: 238–252
- Cohen MG, Tuero E, Bluguermann J, Kevorkian R, Berrocal DH, Carlevaro O, Picabea E, Hudson MP, Siegel RJ, Douthat L, Greenbaum AB, Echt D, Weaver WD, Grinfeld LR. Transcutaneous ultrasound-facilitated coronary thrombolysis during acute myocardial infarction. Am J Cardiol 2003; 92: 454–457
- Demos SM, Onyuksel H, Gilbert J, Roth SI, Kane B, Jungblut P, Pinto JV, McPherson DD, Klegerman ME. In vitro targeting of antibody-conjugated echogenic liposomes for site-specific ultrasonic image enhancement. J Pharm Sci 1997; 86: 167–171
- Demos SM, Dagar S, Klegerman M, Nagaraj A, McPherson DD, Onyuksel H. In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions. J Drug Target 1998; 5: 507–518
- Demos SM, Alkan-Onyuksel H, Kane BJ, Ramani K, Nagaraj A, Greene R, Klegerman M, McPherson DD. In-vivo targeting of acoustically reflective liposomes for intravascular ultrasonic enhancement. J Am Coll Cardiol 1999; 33(3)867–875
- Eccleston DS, Horrigan MC, Ellis SG. Rationale for local drug delivery. Semin Interv Card 1996; 1(1)8–16
- Gurewich V. Fibrinolysis: An unfinished agenda. Blood Coagul Fibrinolysis 2000; 11: 401–408
- Hamilton A, Huang SL, Warnick D, Stein A, Rabbat M, Madhav T, Kane B, Nagaraj A, Klegerman M, MacDonald R, McPherson D. Left ventricular thrombus enhancement following intravenous injection of echogenic immunoliposomes: Studies in a new experimental model. Circulation 2002; 105(23)2772–2778
- Heeremans JL, Gerritsen HR, Meusen SP, Mijnheer FW, Gangaram Panday RS, Prevost R, Kluft C, Crommelin DJ. The preparation of tissue-type plasminogen activator (tPA) containing liposomes: Entrapment efficiency and ultracentrifugation damage. J Drug Target 1995; 3: 301–310
- Holland CK, Vaidya SS, Coussios CC, Shaw GJ. Thrombolytic effects of 120 kHz and 1 MHz ultrasound and tissue plasminogen activator on porcine whole blood clots. J Acoust Soc Am 2002; 112: 2370
- Huang SL, Hamilton AJ, Nagaraj A, Tiukinhoy SD, Klegerman ME, McPherson DD, Macdonald RC. Improving ultrasound reflectivity and stability of echogenic liposomal dispersions for use as targeted ultrasound contrast agents. J Pharm Sci 2001; 90(12)1917–1926
- Klegerman ME, Hamilton AJ, Tiukinhoy SD, Khan AA, Huang SL, MacDonald RC, McPherson DD. Fibrin association characteristics of atheroma-targeted echogenic immunoliposomes. Thromb Vasc Biol 2002; 22(5)214
- Nesheim M, Fredenburgh JC, Larsen GR. The dissociation constants and stoichiometries of the interactions of lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant (FEIX with intact fibrin. J Biol Chem 1990; 265: 21541–21548
- Nordt TK, Bode C. Thrombolysis: Newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89: 1358–1362
- Tiukinhoy-Laing SD, Huang S, Klegerman M, Holland C, MacDonald RC, McPherson DD. Ultrasound-facilitated thrombolysis using tissue-plasminogen activator-loaded echogenic liposomes. Thromb Res 2006, In Press
- Tiukinhoy S, Mahowald M, Shively V, Nagaraj A, Kane B, Klegerman M, MacDonald R, McPherson D, Matsumura J. Development of echogenic, plasmid-incorporated, tissue-targeted cationic liposomes that can be used for directed gene delivery. Investig Radiol 2000; 12: 732–738
- Tiukinhoy S, Khan A, Huang S, Klegerman M, MacDonald R, McPherson D. Novel echogenic drug-immunoliposomes for drug delivery. Investig Radiol 2004; 39: 104–110
- Tsurupa G, Medved L. Fibrinogen αC domains contain cryptic plasminogen and tPA binding sites. Ann NY Acad Sci 2001; 936: 328–330
- Van de Werf FJ. The ideal fibrinolytic: Can drug design improve clinical results?. Eur Heart J 1999; 20: 1452–1458